FeesSafety
Pluang+

NUC-7738 boosts carfilzomib's effectiveness against multiple myeloma in preclinical tests

Market News
20 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
NUC-7738 boosts carfilzomib's effectiveness against multiple myeloma in preclinical tests

NuCana presented preclinical data showing that NUC-7738 enhances the anti-cancer activity of carfilzomib, a drug used to treat multiple myeloma, by increasing proteasome inhibition in cancer cells. The combination significantly reduced cell viability in multiple myeloma cell lines, suggesting a new potential mode of action for NUC-7738 and supporting further clinical evaluation. These findings also indicate broader anti-cancer potential for NUC-7738 in combination therapies across various tumor types. NuCana plans to continue clinical development and explore additional indications and combination strategies.

NuCana's preclinical data on NUC-7738 enhancing carfilzomib activity comes as 77 of 150 health-sector US stocks on Pluang rose today. For readers following health stocks, here is Pluang's market snapshot as of Nov 20, 2026 20:02 WIB: HIMS traded at USD 15.57 with a 2.81% decline and 82% sell order activity, SMMT at USD 10.29 down 2.65% with 100% sell orders, and NUVB at USD 3.71 down 2.62%.

More News

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind usin...

Company Fundamentals
Bullish
48 minutes ago
Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Investors seeking both growth and income can consider a simple ETF portfolio combining the Vanguard Morningstar Growth ETF (VUG) and the Schwab U.S. Dividend Equity ETF (SCHD). VUG focuses on large-cap growth stocks, heavily weighted in technology, w...

Market News
Bullish
1 hour ago
Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid, a decentralized exchange specializing in perpetual futures contracts, is expanding its platform to include real-world assets and prediction markets, aiming to become the "house all of finance." It operates similarly to Amazon's marketpla...

Market News
Bullish
1 hour ago
Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin has dropped below $62,000 after six consecutive weeks of decline, falling more than 50% from its October 2025 peak of around $126,000. The slide was triggered by a combination of factors including a tech sector selloff due to AI valuation con...

Bearish
1 hour ago
Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab reported Q3 sales of $268 million, beating estimates and marking a 73% year-over-year increase, with a backlog growing to $3.6 billion. Despite missing earnings expectations with a loss of $0.12 per share, the company achieved its first fu...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App